Meeting
2012 ASCO Annual Meeting
Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients.
Authors
Giuseppe Procopio
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Giuseppe Procopio , Elena Verzoni , Roberto Iacovelli , Isabella Testa , Roberto Salvioni , Nicola Nicolai , Luca Porcu , Filippo G. De Braud
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Citation
J Clin Oncol 30, 2012 (suppl; abstr 4629)
DOI
10.1200/jco.2012.30.15_suppl.4629
Abstract #
4629
Poster Bd #
8D
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Association of high cost sharing and target therapy initiation among Medicare patients with metastatic renal cell carcinoma.
First Author: Pengxiang Li
Poster
2014 Genitourinary Cancers Symposium
Duration of targeted therapy in metastatic renal cell carcinoma patients with ECOG PS>2.
First Author: Ilya Tsimafeyeu
Poster
2012 Genitourinary Cancers Symposium
Treatment of patients with metastatic renal cell carcinoma (RCC) and end-stage renal disease (ESRD) with targeted therapy (TT): A case series.
First Author: Amber Flaherty
Poster
2012 Genitourinary Cancers Symposium
Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
First Author: Jiahuai Tan